| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
SANT 2 targets the Hedgehog (Hh) signaling pathway as a potent antagonist. It interferes with Gli1 expression, which is a key downstream effector of the Hh pathway. The compound has potential anti-inflammatory and anticancer activity. By inhibiting Hh signaling, SANT 2 modulates cell signaling pathways involved in development, tissue homeostasis, and tumorigenesis. It can be used to study prostate cancer, pancreatic cancer, and breast cancer. Its mechanism involves blocking Smoothened (SMO) or other components of the Hh pathway.
|
|---|---|
| ln Vitro |
In vitro, SANT 2 is a potent Hedgehog signaling pathway antagonist that interferes with Gli1 expression. The compound has potential anti-inflammatory and anticancer activity. It can be used to study prostate cancer, pancreatic cancer, and breast cancer. SANT 2 has been shown to cause developmental delay in medaka embryos, consistent with its role as a Hh pathway antagonist. Detailed in vitro characterization data, including Hh pathway inhibition assays and cell proliferation studies, are available in the primary literature.
|
| ln Vivo |
In vivo studies of SANT 2 have been reported in the context of cancer research. As a Hedgehog signaling pathway antagonist, it has potential for in vivo investigations of cancers driven by aberrant Hh signaling, including Gorlin syndrome (basal cell carcinoma, medulloblastoma, rhabdomyosarcoma), prostate cancer, pancreatic cancer, and breast cancer. SANT 2 causes developmental delay in medaka embryos, confirming its in vivo activity as a Hh pathway antagonist. Specific in vivo efficacy data and detailed animal model studies are available in the primary literature. Further research is ongoing to characterize its full therapeutic potential.
|
| Enzyme Assay |
For Hh signaling pathway assays, cells expressing Hh pathway components are cultured and treated with varying concentrations of SANT 2. Hh pathway activity is assessed by measuring Gli1 expression levels using qRT-PCR or reporter assays. IC50 values for Gli1 inhibition are calculated from dose-response curves. For cell proliferation assays, cancer cell lines are treated with compound and cell viability is assessed using MTT or CCK-8 assays. Assays are performed in triplicate with appropriate vehicle controls and positive controls (e.g., cyclopamine).
|
| Cell Assay |
For in vitro cellular assays, cancer cell lines (e.g., prostate, pancreatic, or breast cancer cells) are cultured in appropriate media under standard conditions (37°C, 5% CO2). SANT 2 is dissolved in DMSO and diluted in culture medium to desired concentrations. Cells are treated with compound for specified durations. Hh pathway activity is assessed by measuring Gli1 expression by qRT-PCR or Western blot. Cell proliferation and viability are assessed using MTT or CCK-8 assays. Apoptosis can be assessed using flow cytometry or caspase activity assays. Each concentration is tested in replicate wells with vehicle controls.
|
| Animal Protocol |
For in vivo animal studies, SANT 2 is typically formulated in suitable vehicles and administered via intraperitoneal (i.p.) injection or oral gavage. Dosing regimens vary by study objective. In cancer models, tumor-bearing animals are treated with compound and tumor growth is monitored. In developmental studies, medaka embryos may be treated with compound and developmental phenotypes are observed. Blood and tissue samples may be collected for pharmacokinetic analysis. All procedures must follow institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of SANT 2 are characteristic of a small-molecule Hedgehog pathway antagonist. The compound has a molecular weight of 479.96, formula C26H26ClN3O4, and CAS number 329196-48-7. Purity: >98.0%. Storage: keep away from direct sunlight, keep away from moisture, store at low temperature, store under nitrogen; powder at -20°C for 3 years; in solvent at -80°C for 1 year. Solubility: DMSO 200 mg/mL (416.7 mM) with sonication. Specific pharmacokinetic parameters are reported in the primary literature.
|
| Toxicity/Toxicokinetics |
According to available safety information, SANT 2 is intended for research purposes only and is not for human use. Standard laboratory safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment (gloves, lab coat, safety goggles). The compound should be handled in a well-ventilated area. Avoid dust formation and inhalation. In case of skin contact, wash with plenty of soap and water. In case of eye contact, rinse cautiously with water for several minutes. No clinical toxicity data are available.
|
| References | |
| Additional Infomation |
SANT 2 is a Hedgehog signaling pathway antagonist with potential anti-inflammatory and anticancer activity. It interferes with Gli1 expression and can be used to study prostate, pancreatic, and breast cancer. It has a molecular weight of 479.96 and formula C26H26ClN3O4. It is for research use only with no clinical development or regulatory approvals reported.
|
| Molecular Formula |
C26H26CLN3O4
|
|---|---|
| Molecular Weight |
479.96
|
| Exact Mass |
479.161
|
| CAS # |
329196-48-7
|
| PubChem CID |
1367095
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.404
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
34
|
| Complexity |
640
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC1=CC(=CC(=C1OCC)OCC)C(=O)NC2=CC(=C(C=C2)Cl)C3=NC4=CC=CC=C4N3
|
| InChi Key |
VQOJFGFKIVFMDH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H26ClN3O4/c1-4-32-22-13-16(14-23(33-5-2)24(22)34-6-3)26(31)28-17-11-12-19(27)18(15-17)25-29-20-9-7-8-10-21(20)30-25/h7-15H,4-6H2,1-3H3,(H,28,31)(H,29,30)
|
| Chemical Name |
N-[3-(1H-benzimidazol-2-yl)-4-chlorophenyl]-3,4,5-triethoxybenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (520.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0835 mL | 10.4175 mL | 20.8351 mL | |
| 5 mM | 0.4167 mL | 2.0835 mL | 4.1670 mL | |
| 10 mM | 0.2084 mL | 1.0418 mL | 2.0835 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
